Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Depreciation & Amortization (CF) (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 26.97% to $2.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $8.1 million, a 4.89% increase, with the full-year FY2025 number at $8.0 million, down 31.07% from a year prior.
  • Depreciation & Amortization (CF) was $2.4 million for Q4 2025 at Kestra Medical Technologies, up from $2.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.5 million in Q2 2024 to a low of $1.8 million in Q2 2025.